Oscar Health reported a jump in its costs to serve customers, bringing down its profitability.
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 20 Aug 2025, 23:16 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The analysis discusses Oscar Health's performance, noting a 22% increase year-to-date and a recent earnings release. While revenue increased to $2.863 billion in the three months ending June 30, 2025, medical costs also jumped significantly to $2.552 billion. Membership grew by 33%, reaching just over 2 million. Management anticipates market stabilization and profitability by 2026. The discounted cash flow valuation model indicates an intrinsic value of $36.37 per share, down from a previous $40. Despite increased costs and decreased profitability, the analyst maintains a buy rating due to the expectation of normalized costs next year. The target is $36.37.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.